Brokerages Expect Inogen Inc (INGN) to Post $0.21 Earnings Per Share

Equities research analysts forecast that Inogen Inc (NASDAQ:INGN) will post earnings of $0.21 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Inogen’s earnings, with estimates ranging from $0.17 to $0.26. Inogen reported earnings per share of $0.25 in the same quarter last year, which indicates a negative year-over-year growth rate of 16%. The company is scheduled to issue its next earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Inogen will report full year earnings of $1.19 per share for the current year, with EPS estimates ranging from $1.17 to $1.21. For the next financial year, analysts expect that the firm will report earnings of $1.48 per share, with EPS estimates ranging from $1.42 to $1.54. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Inogen.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.04. The firm had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The business’s quarterly revenue was up 26.8% compared to the same quarter last year. During the same period last year, the company earned $0.25 EPS.

A number of research analysts have commented on INGN shares. Needham & Company LLC increased their price objective on Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research report on Wednesday, November 8th. Leerink Swann reiterated an “outperform” rating and issued a $120.00 price objective (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective on the stock in a research report on Thursday, November 9th. Finally, BidaskClub lowered Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, December 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $102.71.

In other news, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $119.92, for a total value of $1,678,880.00. Following the transaction, the director now directly owns 7,808 shares in the company, valued at approximately $936,335.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Heath Lukatch sold 2,500 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $126.40, for a total value of $316,000.00. The disclosure for this sale can be found here. Insiders sold a total of 113,651 shares of company stock worth $13,299,463 over the last quarter. Corporate insiders own 5.31% of the company’s stock.

Several large investors have recently bought and sold shares of INGN. Koch Industries Inc. boosted its position in shares of Inogen by 19,485.8% in the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after purchasing an additional 653,747 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Inogen by 24.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after purchasing an additional 301,737 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Inogen by 77.4% in the 2nd quarter. New York State Common Retirement Fund now owns 389,206 shares of the medical technology company’s stock worth $37,138,000 after purchasing an additional 169,778 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Inogen by 91.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 128,043 shares of the medical technology company’s stock worth $12,217,000 after purchasing an additional 61,291 shares during the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of Inogen by 78.2% in the 3rd quarter. Prudential Financial Inc. now owns 124,088 shares of the medical technology company’s stock worth $11,801,000 after purchasing an additional 54,467 shares during the last quarter.

Shares of Inogen (NASDAQ INGN) traded up $3.13 on Friday, reaching $118.12. The company’s stock had a trading volume of 118,040 shares, compared to its average volume of 123,945. The company has a market cap of $2,399.88, a price-to-earnings ratio of 96.03, a price-to-earnings-growth ratio of 3.90 and a beta of 1.13. Inogen has a 52-week low of $62.69 and a 52-week high of $130.05.

COPYRIGHT VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/20/brokerages-expect-inogen-inc-ingn-to-post-0-21-earnings-per-share.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply